Literature DB >> 16086634

Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis.

Samir Malhotra1, Dipika Bansal, Nusrat Shafiq, Promila Pandhi, Bhushan Kumar.   

Abstract

Psoriasis is a chronic inflammatory condition affecting 1 - 3% of the world's population. Despite the availability of several agents, therapeutic options remain limited. With a better understanding of the pathophysiology of psoriasis, several potential therapeutic targets have been identified. Peroxisome proliferator activated receptors have been shown to play a role in cutaneous homeostasis. This review focuses on the potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis and the possibility for the future prospects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086634     DOI: 10.1517/14656566.6.9.1455

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Lipid disturbances in psoriasis: an update.

Authors:  Aldona Pietrzak; Anna Michalak-Stoma; Grazyna Chodorowska; Jacek C Szepietowski
Journal:  Mediators Inflamm       Date:  2010-07-20       Impact factor: 4.711

2.  Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo.

Authors:  Katrin Hack; Louise Reilly; Colin Palmer; Kevin D Read; Suzanne Norval; Robert Kime; Kally Booth; John Foerster
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

3.  Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese.

Authors:  Chin-Hsiao Tseng
Journal:  BMC Cancer       Date:  2015-02-06       Impact factor: 4.430

4.  Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).

Authors:  Surjit Singh; Anil Bhansali
Journal:  BMC Dermatol       Date:  2016-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.